SCHEMBL5116653

SCHEMBL5116653

Cc1ccc(S(=O)(=O)n2ccc3c(NC(C)(C)C)nc(I)nc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.45
LATS1 O95835 2/20 0.40
ACVR1 Q04771 1/20 0.38
BRD4 O60885 1/20 0.37
NOD1 Q9Y239 2/20 0.36
POLB P06746 1/20 0.36
ALDH3A1 P30838 1/20 0.36
HTT P42858 1/20 0.36
NOD2 Q9HC29 1/20 0.36
ATR Q13535 1/20 0.35
ATRIP Q8WXE1 1/20 0.35
RAPGEF4 Q8WZA2 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
PKM P14618 2/20 0.34
HTR6 P50406 3/20 0.34
KDM4E B2RXH2 1/20 0.33
UBE2N P61088 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14547826 0.89 L3MBTL1 (0.48) L3MBTL1LATS1ACVR1BRD4NOD1
SCHEMBL14547788 0.86 L3MBTL1 (0.45) L3MBTL1LATS1ACVR1BRD4NOD1
SCHEMBL5124659 0.84 L3MBTL1 (0.45) L3MBTL1ACVR1BRD4NOD1POLB
SCHEMBL5113381 0.84 L3MBTL1 (0.45) L3MBTL1ACVR1BRD4NOD1POLB
SCHEMBL5116808 0.82 L3MBTL1 (0.42) L3MBTL1ACVR1BRD4NOD1POLB
SCHEMBL5117141 0.81 L3MBTL1 (0.43) L3MBTL1ACVR1BRD4NOD1POLB
SCHEMBL5124281 0.80 L3MBTL1 (0.42) L3MBTL1ACVR1BRD4NOD1POLB
SCHEMBL4793803 0.79 L3MBTL1 (0.50) L3MBTL1BRD4NOD1POLBALDH3A1
SCHEMBL12085380 0.75 HPGD (0.45) L3MBTL1ACVR1POLBATRATRIP
SCHEMBL12510363 0.74 L3MBTL1 (0.39) L3MBTL1ACVR1HTR6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004295-A1 NOVEL COMPOUNDS SYK, BTK, LCK L3MBTL1 3847/4885LATS1 959/4885ACVR1 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.